After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for amyotrophic lateral sclerosis (ALS) – with an elevated status among its pipel
Cancer Research UK has provided £5.9 million ($7.7 million) in funding to a project that will explore the use of artificial intelligence in trials of radiotherapy treatments as well as virt
